Results 221 to 230 of about 3,182,211 (266)

False-Positive Anti-HCV in Biliary Cirrhosis

Annals of Internal Medicine, 1991
To the Editors: A high prevalence of anti-hepatitis C virus (HCV) antibodies detected by enzyme immunoassay (HCV-EIA, Ortho) (1) has been reported in patients with various liver diseases, particula...
C, Housset, C, Hirschauer, F, Degos
openaire   +2 more sources

Sensitivity of an anti‐HCV core peptide ELISA

Journal of Medical Virology, 1992
AbstractA newly developed antibody assay based on a synthetic peptide of 15 amino acids derived from the core region of the hepatitis C virus (HCV) genome was evaluated in serum and plasma panels of (A) 225 haemophiliacs and (B) 44 patients with chronic non‐A, non‐B (NANB) hepatitis, and in (C) sequential serum samples of 9 patients with transfusion ...
Bresters, D., Reesink, H. W., Cuypers, H. T., Jansen, P. L., Mauser-Bunschoten, E. P., van der Poel, C. L., Lelie, P. N.   +6 more
openaire   +2 more sources

[Anti HCV drugs--ribavirin, telaprevir].

Nihon rinsho. Japanese journal of clinical medicine, 2012
The goal of treatment of chronic hepatitis C is the elimination of HCV. Ribavirin and telaprevir are currently used with interferon. In patients with genotype 2 HCV, PEG-IFN+ RBV combination therapy is very effective, but in patients with genotype 1, only SVR can be achieved in only approximately 50%. Furthermore in genotype 1, viral factors i.e. ISDR,
Minoru, Sakamoto, Nobuyuki, Enomoto
openaire   +1 more source

Pathological Consequences in Anti-HCV Antibody-Positive Organ Donation to an Anti-HCV Antibody-Negative Recipient

Transplantation Proceedings
The need to expand the pool of available organs for transplantation has meant that the use of marginal organs is increasingly widespread. The advent of antiviral therapy for hepatitis C virus (HCV) has made it possible to consider the donation of organs from HCV-positive donors and even from viremic donors.In HCV-positive to HCV-negative antibody donor
Anna Rossetto, Gian Luigi Adani, Umberto Baccarani, Patrizia Tulissi, Vittorio Bresadola   +4 more
openaire   +2 more sources

Anti-HCV et hémoglobinopathies

Revue Française de Transfusion et d'Hémobiologie, 1990
B, Mattlinger, A M, Couroucé, R, Girot
openaire   +2 more sources

ISG12a inhibits HCV replication and potentiates the anti-HCV activity of IFN-α through activation of the Jak/STAT signaling pathway independent of autophagy and apoptosis.

Virus Research, 2017
Yanzhao Chen, B. Jiao, Min Yao, Xuezhen Shi, Zhebin Zheng, Shilin Li, Limin Chen   +6 more
semanticscholar   +1 more source

Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios.

Journal of Hepatology, 2015
I. Wolffram, D. Petroff, O. Bätz, K. Jedrysiak, Jan Kramer, H. Tenckhoff, T. Berg, J. Wiegand   +7 more
semanticscholar   +1 more source

Long term stability of HBsAg, anti-HBc and anti-HCV in dried blood spot samples and eluates.

Journal of Clinical Virology, 2015
G. McAllister, S. Shepherd, K. Templeton, C. Aitken, R. Gunson   +4 more
semanticscholar   +1 more source

Natural anti-HCV agents

Drugs of the Future, 2009
null Fan, H., null Starks, C.M., null Hughey, H., null Eldridge, G.R., null Hu, J.-F.   +4 more
openaire   +1 more source